<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552629</url>
  </required_header>
  <id_info>
    <org_study_id>CQGE031X2201</org_study_id>
    <secondary_id>2011-002112-84</secondary_id>
    <nct_id>NCT01552629</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The study will assess the safety and efficacy of QGE031 in the treatment of moderate to&#xD;
      severe atopic dermatitis patients. In addition, QGE031 levels in the blood will be measured&#xD;
      and the effect of QGE031 on markers in the blood and skin will be evaluated. Comparisons of&#xD;
      the effect of QGE31 will be made with placebo and also cyclosporine, a treatment already&#xD;
      established as being effective in atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2012</start_date>
  <completion_date type="Actual">August 28, 2013</completion_date>
  <primary_completion_date type="Actual">August 28, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Eczema Area and Severity Index(EASI)</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Efficacy response will be assessed using EASI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Investigator Global Assessment (IGA) for atopic dermatitis</measure>
    <time_frame>6 weeks, 12 weeks</time_frame>
    <description>Participants dermatitis will be visually assessed and an IGA score will be determined by the Investigator using a prespecified evaluation criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse events will be determined by observation and non-leading questioning of patients, and by measuring safety parameters (electrocardiograms, clinical laboratory, blood pressure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QGE031 plasma concentrations</measure>
    <time_frame>24 weeks</time_frame>
    <description>Blood samples will be collected on Day 1(predose),15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, and 169 for determination of QGE031 serum levels</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Group 1 QGE031</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QGE031 will be administered as a subcutaneous dose q2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A QGE031 matched placebo will be administered as a subcutaneous dose q2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Cyclosporine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine A will be administered (as per label) for atopic dermatitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QGE031</intervention_name>
    <arm_group_label>Group 1 QGE031</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 2 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <arm_group_label>Group 3 Cyclosporine A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion criteria:&#xD;
&#xD;
          -  Male and female patients 18 to 65 years of age inclusive (at the time of the screening&#xD;
             visit), and who passed screening examinations by past medical history, physical&#xD;
             examination, vital signs, electrocardiogram, and laboratory tests.&#xD;
&#xD;
          -  Presence of atopic dermatitis confirmed by itchy skin condition in the past 12 months&#xD;
             (must have), plus three, or more, of the following:&#xD;
&#xD;
               1. History of involvement of the skin creases (fronts of elbows, behind knees,&#xD;
                  fronts of ankles, around neck or around eyes)&#xD;
&#xD;
               2. Personal history of asthma or hay fever&#xD;
&#xD;
               3. History of generally dry skin in the past year&#xD;
&#xD;
               4. Onset before age of 2 years&#xD;
&#xD;
               5. Visible flexural dermatitis&#xD;
&#xD;
          -  Patients with an EASI score of â‰¥20 at screening and stable AD (not currently&#xD;
             experiencing an acute flare of their AD or had a significant change in the extent of&#xD;
             their disease or their treatment regimen in the month prior to enrollment)&#xD;
&#xD;
          -  Patients with a Total IgE in the range of 30 to 5000 IU/mL inclusive&#xD;
&#xD;
        Key exclusion criteria:&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive human chorionic gonadotropin (hCG) laboratory test&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP), defined as all women physiologically capable&#xD;
             of becoming pregnant, including women whose career, lifestyle, or sexual orientation&#xD;
             precludes intercourse with a male partner and women whose partners had been sterilized&#xD;
             by vasectomy or other means unless they were using a highly effective method of birth&#xD;
             control:&#xD;
&#xD;
          -  Total abstinence&#xD;
&#xD;
          -  Male/female sterilization&#xD;
&#xD;
          -  Combination of any two of the following (a+b or a+c or b+c):&#xD;
&#xD;
               1. Use of oral, injected or implanted hormonal methods of contraception&#xD;
&#xD;
               2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)&#xD;
&#xD;
               3. Barrier methods of contraception: condom or occlusive cap (diaphragm or&#xD;
                  cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/exd.13200/epdf</url>
    <description>Abstract for CQGE031X2201</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Atopic eczema</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>QGE031</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

